These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 21600141)

  • 21. [Secondary prevention of patients with ischaemic heart disease--the reduction of LDL cholesterol level and the regression of atherosclerosis].
    Bárczi G; Merkely B
    Lege Artis Med; 2007 Oct; 17(10):675-9. PubMed ID: 19227597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: the Atherosclerosis Risk in Communities Study Cohort.
    Miedema MD; Lopez FL; Blaha MJ; Virani SS; Coresh J; Ballantyne CM; Folsom AR
    JAMA Intern Med; 2015 Jan; 175(1):138-40. PubMed ID: 25401375
    [No Abstract]   [Full Text] [Related]  

  • 23. More reasons statin drugs are shunned.
    Accad M
    Am J Cardiol; 2011 Mar; 107(6):957. PubMed ID: 21376932
    [No Abstract]   [Full Text] [Related]  

  • 24. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicare-eligible patients diagnosed with atherosclerosis: patterns in statin therapy and lipid monitoring.
    Ohsfeldt RL; Gandhi SK; Fox KM
    Curr Med Res Opin; 2009 Jun; 25(6):1403-11. PubMed ID: 19422282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis.
    Herman AG; Moncada S
    Eur Heart J; 2005 Oct; 26(19):1945-55. PubMed ID: 15911567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosuvastatin and progression of atherosclerosis.
    Nicholls SJ
    Expert Rev Cardiovasc Ther; 2008 Aug; 6(7):925-33. PubMed ID: 18666843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Erectile dysfunction and statin treatment in high cardiovascular risk patients.
    Solomon H; Samarasinghe YP; Feher MD; Man J; Rivas-Toro H; Lumb PJ; Wierzbicki AS; Jackson G
    Int J Clin Pract; 2006 Feb; 60(2):141-5. PubMed ID: 16451283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
    Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ
    Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [To give or not to give? Towards the indication of CSE inhibitors ("statins")].
    Teichert M; Lüer AK; Stichtenoth DO
    Med Monatsschr Pharm; 2008 May; 31(5):184-5. PubMed ID: 18552075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selecting Patients for Statin Therapy in Primary Prevention: If We Could Only Predict the Future.
    Bittner V
    J Am Coll Cardiol; 2015 Dec; 66(24):2710-2712. PubMed ID: 26700833
    [No Abstract]   [Full Text] [Related]  

  • 32. Regarding "Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study".
    Goldstein MR; Mascitelli L; Pezzetta F
    J Vasc Surg; 2009 Jun; 49(6):1632-3; author reply 1633. PubMed ID: 19497532
    [No Abstract]   [Full Text] [Related]  

  • 33. Might the beneficial effects of statin drugs be related to their action on iron metabolism?
    Mascitelli L; Goldstein MR
    QJM; 2012 Dec; 105(12):1225-9. PubMed ID: 23097387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention and treatment of atherosclerosis: a practitioner's guide for 2008.
    Lewis SJ
    Am J Med; 2009 Jan; 122(1 Suppl):S38-50. PubMed ID: 19110087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease].
    da Silva PM
    Rev Port Cardiol; 1999 Jan; 18(1):65-76. PubMed ID: 10091528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A peri-operative statin update for non-cardiac surgery. Part I: The effects of statin therapy on atherosclerotic disease and lessons learnt from statin therapy in medical (non-surgical) patients.
    Biccard BM
    Anaesthesia; 2008 Jan; 63(1):52-64. PubMed ID: 18086071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary prevention of atherosclerotic vascular disease.
    Burgess LJ; Sulzer NU
    SADJ; 2010 Aug; 65(7):316-9. PubMed ID: 21133234
    [No Abstract]   [Full Text] [Related]  

  • 38. [About: pleiotropic effects of statins in atherosclerosis].
    Ambrosi P
    Arch Mal Coeur Vaiss; 2005 Dec; 98(12):1263; author reply 1263-5. PubMed ID: 16435610
    [No Abstract]   [Full Text] [Related]  

  • 39. Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin.
    Kotyla PJ; Sliwinska-Kotyla B; Kucharz EJ
    J Rheumatol; 2006 Nov; 33(11):2361-3; author reply 2363. PubMed ID: 17086617
    [No Abstract]   [Full Text] [Related]  

  • 40. Coenzyme A reductase inhibitors and stroke.
    Crouse JR
    Ann Intern Med; 1998 Jul; 129(2):161; author reply 162. PubMed ID: 9669980
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.